These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Current strategies to improve the safety of chimeric antigen receptor (CAR) modified T cells. Yang QY; Yang JD; Wang YS Immunol Lett; 2017 Oct; 190():201-205. PubMed ID: 28837818 [TBL] [Abstract][Full Text] [Related]
23. Moving from tinkering in the garage to assembly line production: the manufacture of genetically modified T cells expressing chimeric antigen receptors (CARs) comes on line. Cooper LJ Cancer Gene Ther; 2015 Mar; 22(2):64-6. PubMed ID: 25675874 [No Abstract] [Full Text] [Related]
24. Cancer immunotherapy utilizing gene-modified T cells: From the bench to the clinic. Duong CP; Yong CS; Kershaw MH; Slaney CY; Darcy PK Mol Immunol; 2015 Oct; 67(2 Pt A):46-57. PubMed ID: 25595028 [TBL] [Abstract][Full Text] [Related]
25. T-cell adoptive immunotherapy using tumor-infiltrating T cells and genetically engineered TCR-T cells. Ikeda H Int Immunol; 2016 Jul; 28(7):349-53. PubMed ID: 27127191 [TBL] [Abstract][Full Text] [Related]
27. Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Kalos M; June CH Immunity; 2013 Jul; 39(1):49-60. PubMed ID: 23890063 [TBL] [Abstract][Full Text] [Related]
30. Rebalancing immune specificity and function in cancer by T-cell receptor gene therapy. Udyavar A; Geiger TL Arch Immunol Ther Exp (Warsz); 2010 Oct; 58(5):335-46. PubMed ID: 20680493 [TBL] [Abstract][Full Text] [Related]
31. Challenges and prospects of chimeric antigen receptor T cell therapy in solid tumors. Jindal V; Arora E; Gupta S Med Oncol; 2018 May; 35(6):87. PubMed ID: 29730801 [TBL] [Abstract][Full Text] [Related]
32. Chimeric antigen receptor T-cell therapy for cancer: a basic research-oriented perspective. Han C; Kwon BS Immunotherapy; 2018 Mar; 10(3):221-234. PubMed ID: 29370727 [TBL] [Abstract][Full Text] [Related]
33. Re-adapting T cells for cancer therapy: from mouse models to clinical trials. Stromnes IM; Schmitt TM; Chapuis AG; Hingorani SR; Greenberg PD Immunol Rev; 2014 Jan; 257(1):145-64. PubMed ID: 24329795 [TBL] [Abstract][Full Text] [Related]
34. Genetically Modified T-Cell-Based Adoptive Immunotherapy in Hematological Malignancies. Ye B; Stary CM; Gao Q; Wang Q; Zeng Z; Jian Z; Gu L; Xiong X J Immunol Res; 2017; 2017():5210459. PubMed ID: 28116322 [TBL] [Abstract][Full Text] [Related]
35. T-cell-based Immunotherapy: Adoptive Cell Transfer and Checkpoint Inhibition. Houot R; Schultz LM; Marabelle A; Kohrt H Cancer Immunol Res; 2015 Oct; 3(10):1115-22. PubMed ID: 26438444 [TBL] [Abstract][Full Text] [Related]
36. Adoptive T-cell therapy for cancer: The era of engineered T cells. Bonini C; Mondino A Eur J Immunol; 2015 Sep; 45(9):2457-69. PubMed ID: 26202766 [TBL] [Abstract][Full Text] [Related]
37. CART trials are going ahead. Wei J; Han W Sci China Life Sci; 2017 Nov; 60(11):1276-1279. PubMed ID: 29170890 [No Abstract] [Full Text] [Related]
38. Functional design of chimeric T-cell antigen receptors for adoptive immunotherapy of cancer: architecture and outcomes. Shirasu N; Kuroki M Anticancer Res; 2012 Jun; 32(6):2377-83. PubMed ID: 22641678 [TBL] [Abstract][Full Text] [Related]
39. Moving receptor redirected adoptive cell therapy toward fine tuning of antitumor responses. Chicaybam L; Bonamino MH Int Rev Immunol; 2014 Oct; 33(5):402-16. PubMed ID: 24911925 [TBL] [Abstract][Full Text] [Related]